Neurocognitive Functioning and Genetic Variation in Patients with Primary Brain Tumours

Overview

Journal Lancet Oncol

Specialty Oncology

Date 2016 Mar 15

PMID 26972863

Citations 37

Authors

Jeffrey S Wefel

Kyle R Noll

Michael E Scheurer

Affiliations

Soon will be listed here.

Abstract

Impairment of neurocognitive functioning is a common result of cerebral neoplasms and treatment, although there is substantial heterogeneity in the pattern and severity of neurocognitive dysfunction across individuals and tumour types. The effects of many clinical and patient characteristics on neurocognitive functioning have been documented, but little research has been devoted to understanding the effect of genetic variation on neurocognitive outcomes in patients with brain tumours. This Review highlights preliminary evidence that suggests an association between various genes and risk of adverse neurocognitive outcomes in patients with brain tumours. Studies include genes specific to neuronal function, and those associated with more systemic cellular regulation. Related scientific literature in other disease populations is briefly discussed to indicate additional candidate genes. We consider methodological issues central to the study of neurocognitive functioning and genetic associations for patients with brain tumours, and emphasise the need for future research integrating novel investigative techniques.

Citing Articles

ICAM-1 and IL-10 are associated with cognitive dysfunction using the MoCA test in glioma: Findings from the NCI Neuro-Oncology Branch Natural History Study.

Slattery K, Kauss M, Raval D, Hsieh E, Choi A, Davis T Neurooncol Adv. 2025; 7(1):vdaf002.

PMID: 40041201 PMC: 11879401. DOI: 10.1093/noajnl/vdaf002.

Glioblastoma-derived migrasomes promote migration and invasion by releasing PAK4 and LAMA4.

Huang Z, Wang M, Chen Y, Tang H, Tang K, Zhao M Commun Biol. 2025; 8(1):91.

PMID: 39833606 PMC: 11747271. DOI: 10.1038/s42003-025-07526-w.

The value of systemic immune inflammation index, white blood cell to platelet ratio, and homocysteine in predicting the instability of small saccular intracranial aneurysms.

Zhang W, Xiang C, Liu B, Hou F, Zheng Z, Chen Z Sci Rep. 2024; 14(1):24312.

PMID: 39414876 PMC: 11484959. DOI: 10.1038/s41598-024-74870-y.

Neuropsychological Evaluation for Oncology.

Sheppard D, Noll K, Wefel J, Bradshaw M Neurol Clin. 2024; 42(4):875-887.

PMID: 39343481 PMC: 11443061. DOI: 10.1016/j.ncl.2024.05.012.

Understanding treatment preferences and cognitive outcomes in patients with gliomas.

Succop Jr B, Richardson D, Rauf Y, Higgins D, Catalino M Support Care Cancer. 2024; 32(10):673.

PMID: 39292365 DOI: 10.1007/s00520-024-08876-7.

References

Brackett J, Krull K, Scheurer M, Liu W, Srivastava D, Stovall M . Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study. Neuro Oncol. 2012; 14(8):1018-25. PMC: 3408256. DOI: 10.1093/neuonc/nos123. View

Waterhouse E, An J, Orefice L, Baydyuk M, Liao G, Zheng K . BDNF promotes differentiation and maturation of adult-born neurons through GABAergic transmission. J Neurosci. 2012; 32(41):14318-30. PMC: 3519245. DOI: 10.1523/JNEUROSCI.0709-12.2012. View

Lio D, Annoni G, Licastro F, Crivello A, Forte G, Scola L . Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev. 2006; 127(6):567-71. DOI: 10.1016/j.mad.2006.01.015. View

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot M . Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006; 12(10):3050-6. DOI: 10.1158/1078-0432.CCR-05-2076. View

Mandelblatt J, Hurria A, McDonald B, Saykin A, Stern R, VanMeter J . Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?. Semin Oncol. 2013; 40(6):709-25. PMC: 3880205. DOI: 10.1053/j.seminoncol.2013.09.006. View

Brouwers P . Commentary: study of the neurobehavioral consequences of childhood cancer: entering the genomic era?. J Pediatr Psychol. 2004; 30(1):79-84. DOI: 10.1093/jpepsy/jsi018. View

Lin N, Lee E, Aoyama H, Barani I, Baumert B, Brown P . Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013; 14(10):e396-406. DOI: 10.1016/S1470-2045(13)70311-5. View

Sorrentino B . Chemoprotection in brain tumor patients: another success for stem cell gene therapy. Mol Ther. 2012; 20(8):1485-7. PMC: 3412487. DOI: 10.1038/mt.2012.139. View

10.

Mulhern R, Palmer S, Merchant T, Wallace D, Kocak M, Brouwers P . Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005; 23(24):5511-9. DOI: 10.1200/JCO.2005.00.703. View

11.

Moore 3rd B, Ater J, Copeland D . Improved neuropsychological outcome in children with brain tumors diagnosed during infancy and treated without cranial irradiation. J Child Neurol. 1992; 7(3):281-90. DOI: 10.1177/088307389200700308. View

12.

Howarth R, Adamson A, Ashford J, Merchant T, Ogg R, Schulenberg S . Investigating the relationship between COMT polymorphisms and working memory performance among childhood brain tumor survivors. Pediatr Blood Cancer. 2013; 61(1):40-5. PMC: 4101980. DOI: 10.1002/pbc.24649. View

13.

Mulhern R, Khan R, Kaplan S, Helton S, Christensen R, Bonner M . Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol. 2004; 22(23):4795-803. DOI: 10.1200/JCO.2004.04.128. View

14.

Longhi L, Perego C, Ortolano F, Aresi S, Fumagalli S, Zanier E . Tumor necrosis factor in traumatic brain injury: effects of genetic deletion of p55 or p75 receptor. J Cereb Blood Flow Metab. 2013; 33(8):1182-9. PMC: 3734767. DOI: 10.1038/jcbfm.2013.65. View

15.

Stefanis N, van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Stefanis C . Effect of COMT Val158Met polymorphism on the Continuous Performance Test, Identical Pairs Version: tuning rather than improving performance. Am J Psychiatry. 2005; 162(9):1752-4. DOI: 10.1176/appi.ajp.162.9.1752. View

16.

Pencina M, DAgostino Sr R, Demler O . Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Stat Med. 2011; 31(2):101-13. PMC: 3341978. DOI: 10.1002/sim.4348. View

17.

McAllister T, Ahles T, Saykin A, Ferguson R, McDonald B, Lewis L . Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatry Rep. 2004; 6(5):364-71. DOI: 10.1007/s11920-004-0023-y. View

18.

Kamath A, Chauhan A, Kisucka J, Dole V, Loscalzo J, Handy D . Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood. 2005; 107(2):591-3. PMC: 1895614. DOI: 10.1182/blood-2005-06-2506. View

19.

. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288(16):2015-22. DOI: 10.1001/jama.288.16.2015. View

20.

Ahles T, Saykin A, Noll W, Furstenberg C, Guerin S, Cole B . The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003; 12(6):612-9. DOI: 10.1002/pon.742. View